Serina Therapeutics replaces Withum with Frazier & Deeter as auditor after merger

Serina Therapeutics, Inc.

Audit committee approved Frazier & Deeter as independent auditor for FY2024, replacing Withum.
Withum's reports for FY2022 and FY2023 had no adverse opinion except going concern doubt.
No disagreements with Withum on accounting principles or audit scope during those periods.
Withum provided a letter (Exhibit 16.1) agreeing with the disclosures in this filing.

item 4.01 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Auditor Changes SEC 8-K Item 4.01/4.02 confidence 0.9

Serina Therapeutics, Inc. dismissed WithumSmith+Brown, PC as its auditor.

Action: dismissal
Auditor: WithumSmith+Brown, PC
Successor: Frazier & Deeter, LLC

Exact text from the filing

ithumSmith+Brown, PC (“ Withum ”), the Company’s independent registered public accounting firm prior to the Merger, was informed that it would be dismissed and replaced by Frazier & Deeter. The reports of Withum on the Company’s financial statements for each of the two fiscal years ended December 31, 2023 and 2022 did not

View on SEC.gov

Auditor Changes SEC 8-K Item 4.01/4.02 confidence 0.9

Serina Therapeutics, Inc. engaged Frazier & Deeter, LLC as its auditor.

Action: engagement
Auditor: Frazier & Deeter, LLC

Exact text from the filing

pril 29, 2024, the Audit Committee of the Board of Directors of the Company approved, on behalf of the Company, the engagement of Frazier & Deeter, LLC (“ Frazier & Deeter ”) as the Company’s independent registered public accounting

View on SEC.gov

47 auditor changes filed in the last 30 days. Browse all auditor changes →

Serina Therapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0001493152-24-017731

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.